Integrated respiratory surveillance turns routine testing into readiness.
A laboratory network becomes an early-warning system only when specimens, testing, quality controls, epidemiological context and reporting are designed to work together. Adding more targets to a test can increase the information produced from a specimen; it does not, by itself, make that information representative, comparable or actionable.
WHO's Global Respiratory Virus Activity Weekly Update No. 592, covering week 33 ending 16 August 2026, reported global influenza positivity below 10%, SARS-CoV-2 activity stable and low across most reporting countries, and RSV positivity low globally. The same update identified countries and zones with elevated or increasing activity, showing why global averages should not be treated as a description of every local setting.
A low global average can contain important local signals
WHO reported influenza positivity above 10% in countries across several tropical and northern-hemisphere zones, while SARS-CoV-2 positivity was elevated in countries in Central America and the Caribbean and in individual countries in Tropical South America, Southern Asia and South-East Asia. RSV positivity was also elevated in several countries, including a value above 30% in one country in Temperate South America.
Vision interpretation: preparedness decisions should be based on country and subnational signals, specimen sources and time trends—not a single global headline. A network must be able to preserve the context behind each result so that an increase in positivity can be distinguished from a change in who was tested, where specimens were collected or how reporting was performed.
Integration is an end-to-end operating model
WHO's standards and operational guidance, published 4 December 2024, defines integrated GISRS surveillance as the full process from systematic screening and respiratory-specimen collection through testing, sequencing, data sharing and analysis. The guidance uses the influenza surveillance platform to support the integration of SARS-CoV-2 and RSV and supersedes earlier separate guidance documents.
This definition matters because a combined laboratory result is only one step. If case definitions differ between sites, specimens are collected at inconsistent times, denominators are missing or data arrive late, the resulting trend may not be comparable across places or weeks. Integration must therefore connect epidemiology and laboratory operations under a shared surveillance objective.
Design the question before choosing the panel
Vision interpretation: every integrated surveillance programme should begin by defining the decisions it needs to support. Routine monitoring, seasonal characterization, severity assessment, detection of unusual events and sequencing selection may require different sampling strategies and laboratory pathways.
- Surveillance objective: define which public-health questions the network must answer and which indicators will be reported.
- Sentinel design: select sites, populations, case definitions, sampling frequency and denominators that can produce interpretable trends.
- Specimen pathway: standardise collection, labelling, acceptance, transport, storage and referral criteria.
- Testing algorithm: document which specimens are tested for which targets, how invalid or discordant results are managed, and when characterization or sequencing is required.
- Data pathway: preserve specimen source, timing, method and quality information while using authorised, secure reporting routes.
- Review cycle: monitor completeness, timeliness, positivity, target performance and site-level deviations before interpreting changes.
Quality must remain visible when targets are combined
WHO reported that its External Quality Assessment Programme expanded from influenza RT-PCR to include SARS-CoV-2 in 2020, with RSV included as a pilot component from 2023. WHO also described newly designated Collaborating Centres in Senegal and Hong Kong SAR, China as supporting laboratory quality systems, workforce development, assay development, performance assessment and integrated surveillance.
A multiplex workflow can simplify specimen use and laboratory handling, but each target still requires performance monitoring within its validated scope. Controls must show that the complete process is functioning; acceptance criteria, contamination management, equipment verification, lot transition and operator competency should be documented. Changes in circulating viruses, primers, probes, software or suppliers need defined review and change-control pathways.
Vision interpretation: a surveillance network should be able to explain not only what it detected, but why the result is trustworthy and comparable with previous reporting periods. Internal quality control, external quality assessment, trend review and referral to competent reference laboratories are complementary controls—not interchangeable labels.
A shared network is also a surge-capacity platform
WHO describes GISRS as a continuously operating mechanism for surveillance, preparedness and response and reports that it currently comprises 166 institutions across 136 WHO Member States. RespiMart brings together respiratory-virus surveillance data, including influenza, SARS-CoV-2 and RSV, through the FluNet and FluID databases.
Routine surveillance keeps specimen routes, equipment, reporting interfaces and laboratory skills active between emergencies. That operating base can support faster adaptation during a respiratory event, provided surge roles, reserve capacity, referral links and authority responsibilities are agreed in advance.
Supply planning should cover the complete workflow: swabs and transport media, extraction materials, controls, reagents, plastics, cold-chain capacity, calibration, maintenance and data connectivity. Local or regional production may reduce selected dependencies, but only when transferred processes, materials, lot release, stability, regulatory obligations and post-market responsibilities remain controlled.
Reporting limitations are part of the evidence
WHO states that countries, areas and territories use different approaches to monitor respiratory-virus activity and that figures in the weekly update may differ from other surveillance reports. The update includes sentinel surveillance and other systematically conducted virological surveillance; analyses can be stratified by surveillance source through RespiMart.
Vision interpretation: an integrated dashboard should not imply that missing reports equal zero activity or that all countries contribute comparable data. Data cut-off dates, coverage, testing volume, source populations, method changes and revisions should travel with the headline indicator.
The Vision Biotechnology response lens
Vision Biotechnology approaches integrated respiratory surveillance as a network-design and quality-system programme. A practical engagement can begin with surveillance-objective mapping, laboratory and referral-network assessment, workflow and equipment planning, quality-control architecture, workforce training, data-interface requirements and continuity modelling for routine and surge demand.
Where localisation is appropriate, the same programme should define the exact technology-transfer scope, supplier qualification, process verification, lot-release responsibilities, stability oversight and country-specific regulatory pathway before production claims are made. Test selection and implementation remain the responsibility of authorised health and regulatory institutions and must reflect validated intended use, national algorithms and local epidemiology.
Do not measure integration by the number of targets on a panel. Measure whether the network can collect comparable specimens, produce controlled results, preserve epidemiological context, report on time and expand responsibly when the next respiratory threat appears.
Primary sources
This article separates WHO-published information from Vision Biotechnology interpretation. It provides general public-health, laboratory and quality-system information; it is not medical advice, a diagnostic recommendation, regulatory approval or a claim about any specific Vision product. National authorities and applicable laboratory procedures remain controlling.